Q-omics provides the consensus-scored MIR4713HG profile across patient tissues and cancer cell-line models. MIR4713HG expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MIR4713HG is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, MIR4713HG RNA expression shows 13,856 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, and THYM as cancer lineages where MIR4713HG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4713HG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4713HG survival associations across molecular data types. MIR4713HG RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4713HG RNA expression–survival associations across cancer types. High MIR4713HG expression shows unfavorable associations in HNSC, COAD, MESO and LUAD, but favorable associations in UCEC and UCS. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for MIR4713HG RNA expression.
This table summarizes MIR4713HG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4713HG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4713HG shows higher tumor expression in HNSC, COAD, LUSC, STAD, LUAD and BLCA. The HNSC box plot shows higher MIR4713HG RNA expression in tumor versus normal tissue (log2 FC = +2.383, t-test p < 0.001).
This table shows molecular features associated with MIR4713HG in patient tissues and cancer cell lines. In patient samples, MIR4713HG shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
